Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma

Nanomedicine

Volumn 9, Issue 1, 2014, Pages 45-60

  Yang, Cuiping ^a   Xiong, Fei ^b   Wang, Jing ^a   Dou, Jun ^a   Chen, Junsong ^a   Chen, Dengyu ^a   Zhang, Yu ^b   Luo, Shouhua ^b   Gu, Ning ^b  

^a SOUTHEAST UNIVERSITY   (China)

^b Southeast University   (China)

Author keywords

anti ABCG2 monoclonal antibody; cancer stem cell; iron oxide nanoparticle; multiple myeloma; paclitaxel; paclitaxel nanoparticle; targeted therapy

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; IRON OXIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ABCG2; NANOPARTICLE; OLEIC ACID; PACLITAXEL; POLOXAMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DENSITY; BONE LESION; CANCER STEM CELL; CARCINOGENICITY; CELL ACTIVITY; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; FERRIC COMPOUNDS; MICE; MULTIPLE MYELOMA; NANOPARTICLES; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PACLITAXEL;

EID: 84896496412     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.216     Document Type: Article

References (41)

1. Giralt S. Stem cell transplantation for multiple myeloma: current and future status. Controversies and updates in multiple myeloma. Hematology 1, 191-196 (2011).
2. Anderson KC. New insights into therapeutic targets in multiple myeloma. Hematology Am. Soc. Hematol. Educ. Program 2011, 184-190 (2011).
3. Ikegame A, Ozaki S, Tsuji D et al. Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia 26(9), 2124-2134 (2012).
4. Dou J, Gu N. Emerging strategies for the identification and targeting of cancer stem cells. Tumour Biol. 31(4), 243-253 (2010).
5. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005).
6. Delude C. Tumorigenesis: testing ground for cancer stem cells. Nature 480(7377), S43-S45 (2011).
7. Matsui W, Borrello I, Mitsiades C. Autologous stem cell transplantation and multiple myeloma cancer stem cells. Bio. Blood Marrow Transplant. 18(Suppl. 1), S27-S32 (2012).
8. Hosen N, Ichihara H, Mugitani A et al. CD48 as a novel molecular target for antibody therapy in multiple myeloma. Br. J. Haematol. 156, 213-224 (2012).
9. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol. Res. Prac. 192, 768-780 (1996).
10. Turner JG, Gump JL, Zhang C et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 108, 3881-3889 (2006).
11. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651 (2002).
12. Feng SS. Chemotherapeutic engineering: concept, feasibility, safety and prospect-a tribute to Shu Chien's 80th birthday. Cell Mol. Bioengineer. 4(4), 708-716 (2011).
13. Yang J, Yi Q. Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. Am. J. Blood. Res. 1(1), 22-33 (2011).
14. Gazitt Y, Shaughnessy P, Rothenberg ML. A Phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients. Oncol. Rep. 16(4), 877-884 (2006).
15. Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA. Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93). Am. J. Clin. Oncol. 21(6), 553-556 (1998).
16. Seo K, Chung SW, Byun Y, Kim D. Paclitaxel loaded nano-aggregates based on pH sensitive polyaspartamide amphiphilic graft copolymers. Int. J. Pharm. 424(1-2), 26-32 (2011).
17. Feng SS, Mu L, Win KY, Guofeng H. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 11(4), 413-424 (2004).
18. Guan N, Liu C, Sun D, Xu J. A facile method to synthesize carboxyl-functionalized magnetic polystyrene nanospheres. Colloids Surf. A Physicochem. Eng. Asp. 335(1-3), 174-180 (2009).
19. Matsui W, Huff CA, Wang Q et al. Characterization of clonogenic multiple myeloma cells. Blood 103(6), 2332-2336 (2004).
20. Hu W, Wang J, Dou J et al. Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice. Cell Transplant. 20(5), 669-680 (2011).
21. Wang J, Zhou D, He X et al. Effect of downregulated b-catenin on cell proliferative activity, the sensitivity to chemotherapy drug and tumorigenicity of ovarian cancer cells. Cell. Mol. Biol. (Noisy-le-Grand) 57(Suppl.), OL1606-OL1613 (2011).
22. Su HY, Lai HC, Lin YW et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int. J. Cancer. 127(3), 555-567 (2010).
23. Dou J, Pan M, Wen P et al. Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell. Mol. Immunol. 4(6), 467-472 (2007).
24. Dou J, Li Y, Zhao F et al. Identification of tumor stem-like cells in a mouse myeloma cell line. Cell. Mol. Biol. (Noisy-le-Grand) 55(Suppl.), OL1151-1160 (2009).
25. Holt RU, Fagerli UM, Baykov V et al. Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 93(4), 619-622 (2008).
26. Hu K, Dou J, Yu F et al. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine 29(7), 1455-1462 (2011).
27. Villa CH, Dao T, Ahearn I et al. Single walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano. 5(7), 5300-5311 (2011).
28. Cirstea D, Hideshima T, Rodig S et al. Dual Inhibition of Akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol. Cancer Ther. 9(4), 963-975 (2010).
29. AshaRani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano. 3(2), 279-290 (2008).
30. Xia T, Kovochich M, Brant J et al. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 6(8), 1794-1807 (2006).
31. DeWeerdt S. Animal models: towards a myeloma mouse. Nature 480(7377), S38-S39 (2011).
32. Liu J, Lau SK, Varma VA et al. Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. ACS Nano. 4(5), 2755-2765 (2010).
33. Agarwal JR, Matsui W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med. Chem. 10(2), 116-120 (2010).
34. Gunn EJ, Williams JT, Huynh DT et al. The natural products parthenolide and andrographolide exhibit anticancer stem cell activity in multiple myeloma. Leuk. Lymphoma 52(6), 1085-1097 (2011).
35. Rowan K. Are cancer stem cells real? After four decades, debate still simmers. J. Natl Cancer. Inst. 101(8), 546-547 (2009).
36. Dou J, Jiang C, Wang J et al. Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol. Int. 35(3), 227-234 (2011).
37. Yu F, Wang J, Dou J et al. Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Nanomedicine 8(8), 1337-1344 (2012).
38. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol. Pharm. 2(3), 194-205 (2005).
39. Zhang Z, Feng SS. Nanoparticles of poly (lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 27(2), 262-270 (2006).
40. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95(3), 1056-1065 (2000).
41. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116(18), 3554-3563 (2010).